SCHEMBL24740256

SCHEMBL24740256

CC(C)NC(=O)COc1ccc(Cl)cc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 1.00
LMNA P02545 2/20 0.74
HPGD P15428 3/20 0.73
NLRP1 Q9C000 1/20 0.73
RECQL P46063 2/20 0.67
TDP1 Q9NUW8 2/20 0.62
TSHR P16473 2/20 0.62
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
RAB9A P51151 3/20 0.58
TP53 P04637 2/20 0.58
NPC1 O15118 2/20 0.58
MAPT P10636 2/20 0.58
PKM P14618 1/20 0.58
MAPK1 P28482 1/20 0.58
ALDH1A1 P00352 2/20 0.57
HTT P42858 2/20 0.57
KCNJ6 P48051 1/20 0.57
KCNJ5 P48544 1/20 0.57
KCNJ3 P48549 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27300755 0.87 SMN1; SMN2 (0.77) SMN1; SMN2LMNAHPGDNLRP1RECQL
SCHEMBL30451475 0.86 SMN1; SMN2 (0.75) SMN1; SMN2LMNAHPGDNLRP1RECQL
SCHEMBL24252836 0.86 SMN1; SMN2 (0.75) SMN1; SMN2LMNAHPGDNLRP1RECQL
SCHEMBL2557610 0.83 SMN1; SMN2 (0.71) SMN1; SMN2LMNAHPGDNLRP1RECQL
SCHEMBL2560314 0.83 SMN1; SMN2 (0.71) SMN1; SMN2LMNAHPGDNLRP1RECQL
SCHEMBL24112746 0.83 TDP1 (0.72) SMN1; SMN2LMNAHPGDRECQLTDP1
SCHEMBL27374826 0.83 SMN1; SMN2 (0.71) SMN1; SMN2LMNAHPGDNLRP1RECQL
SCHEMBL8247489 0.82 KMT2A (0.74) SMN1; SMN2LMNAHPGDTDP1TSHR
SCHEMBL8291109 0.81 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHPGDRECQLTDP1
SCHEMBL7428231 0.81 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHPGDNLRP1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL SMN1; SMN2 4032/4885LMNA 2486/4885HPGD 1608/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV SMN1; SMN2 3613/4885LMNA 2202/4885HPGD 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.